secwatch.observer — SEC 8-K summary
======================================

Issuer:     Prelude Therapeutics Inc (PRLD)
CIK:        0001678660
Form:       8-K
Filed at:   2026-09-10T11:29:55+00:00
Accession:  0001193125-26-387232
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Prelude Therapeutics gets FDA clearance to start Phase 1 trial of PRT13722 for HR+ breast cancer
--------------------------------------------------------------------------------

- FDA cleared IND for PRT13722, an oral KAT6A selective degrader, for HR+/HER2- breast cancer.
- Phase 1 study expected to begin enrolling patients in Q4 2026.
- Study will evaluate PRT13722 as monotherapy and in combination with endocrine and targeted therapies in adults with locally advanced or metastatic HR-positive, HER2-negative breast cancer.
- Company believes selective KAT6A degradation may improve efficacy and hematological safety vs dual KAT6A/B inhibitors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1678660/000119312526387232/0001193125-26-387232-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1678660/000119312526387232/prld-20260910.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-387232

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer